Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.

about

P2860

Q59126189-005166E3-46C3-494A-8D7D-34BA5FC88190

P2860

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.

Item

http://www.wikidata.org/entity/Q39441719

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@en

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@nl

type

Item

label

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@en

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@nl

prefLabel

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@en

Endocrine toxicity of immune c ...... ocrinologists and oncologists.

@nl

P1476

Endocrine toxicity of immune c ...... docrinologists and oncologists

@en

P2093

Claire Briet

http://www.w3.org/2001/XMLSchema#string

Lucie Cloix

http://www.w3.org/2001/XMLSchema#string

Ludovic Martin

http://www.w3.org/2001/XMLSchema#string

Nathalie Baize

http://www.w3.org/2001/XMLSchema#string

Patrice Rodien

http://www.w3.org/2001/XMLSchema#string

Thierry Urban

http://www.w3.org/2001/XMLSchema#string

Yannick Le Corre

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.

P304

1923-1929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1145

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Illouz

P577

2017-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28719055

http://www.w3.org/2001/XMLSchema#string

P921

endocrine system

P932

5548876

http://www.w3.org/2001/XMLSchema#string

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.

about

P2860

P2860

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932